Doricum

Quick links to important sections

Doricum

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Doricum

Quick Facts

Property Description
Active Ingredients Fluocinolone acetonide, Neomycin sulfate
Form Topical Cream or Ointment
Pharmacological Class Topical Corticosteroid and Anti-infective Combination
General Purpose Anti-inflammatory and Antimicrobial Action
Origin Semi-synthetic (Corticosteroid derivative, Aminoglycoside antibiotic)

Doricum: Classification and Formulation Overview

Doricum is a combination medicine formulated exclusively as a topical preparation for external dermal application, frequently requiring a prescription for dispensing. Pharmacologically, it is classified as a Topical Steroid with Anti-infectives, a drug class clinically recognized for treating skin inflammation that is concurrent with, or at high risk of, bacterial infection. The co-presence of the two distinct agents defines its dual therapeutic role. The medicine is prepared as a semi-solid topical cream or ointment, allowing the practitioner to choose the vehicle most suitable for the specific characteristics of the skin condition being managed.

What is the Composition of Doricum?

The product's structure relies on two principal active ingredients: the glucocorticoid Fluocinolone acetonide and the antibiotic Neomycin sulfate. Fluocinolone acetonide is a synthetic corticosteroid compound known for its strong anti-inflammatory action and capacity to moderate the local immune response. Neomycin sulfate is an aminoglycoside antibiotic originally derived from the bacterium Streptomyces fradiae, included specifically to provide localized antimicrobial coverage against susceptible surface organisms. The combination is generally positioned for inflammatory skin conditions in adult and pediatric patients where a medium-to-high potency steroid must be paired with an effective antibiotic.

General Purpose of the Dual-Action Topical

The general therapeutic purpose of Doricum is to provide integrated relief that simultaneously addresses intense inflammation and the need for antimicrobial protection. The combined formulation delivers effective symptomatic relief from signs such as swelling, redness, and itching, while the antibiotic component helps manage potential bacterial proliferation at the application site. The combination of such agents helps manage conditions where the anti-inflammatory effect of the steroid must be coupled with protection against infection. This strategic pairing is designed to facilitate the resolution of both the immune-mediated reaction and the microbial component.

Regulatory References

  1. NIH DailyMed Label for Neo-Synalar
  2. Fluocinolone and Neomycin Topical Drug Information

What side effects are possible with Doricum?

Possible Side Effects and Safety Information

The safety profile for this topical combination is formally structured around the specific risks associated with its two active ingredients: the corticosteroid (Fluocinolone acetonide) and the antibiotic (Neomycin sulfate). This information is based exclusively on official government regulatory documents.

Adverse Reaction Categories

Adverse reactions are classified by the physiological system affected and reported frequency:

  • Dermatological Effects: Reactions at the application site are the most frequently documented side effects, listed as infrequently reported. These include burning, itching, irritation, dryness, folliculitis, acneiform eruptions, and hypopigmentation. Prolonged use is associated with structural changes such as skin atrophy and striae (thinning and stretch marks).
  • Systemic and Organ Disorders: Due to the potential for systemic absorption, reactions affecting distant systems are documented, including Endocrine Disorders (HPA axis suppression, Cushing's syndrome manifestations), Ear and Labyrinth Disorders (Ototoxicity or hearing loss), and Renal Disorders (Nephrotoxicity or kidney damage) primarily linked to the Neomycin component.

Serious Adverse Reactions and Safety Constraints

The most serious adverse reactions are associated with significant systemic absorption, including reversible HPA axis suppression and the potential for irreversible ototoxicity and nephrotoxicity from Neomycin.

Population-Specific Safety: Pediatric patients are officially noted to be more susceptible to systemic toxicity, including HPA axis suppression and growth retardation, due to their higher skin surface area-to-body weight ratio.

Exposure-Related Risk: Regulatory labeling explicitly states that the risk of systemic effects increases significantly with prolonged use, application over a large surface area, use on broken skin, or the use of occlusive dressings.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Doricum

Overdose is primarily linked to the systemic absorption of the active ingredients following prolonged use, application to large areas of skin, or use under occlusive dressings. This systemic exposure is the documented concern for topical products of this combination.

The absorption of the corticosteroid component, Fluocinolone acetonide, may lead to reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing's Syndrome, including hyperglycemia and glucosuria. Systemic exposure to the Neomycin sulfate component carries the potential risk of nephrotoxicity (kidney damage) and ototoxicity (hearing problems or ringing in the ears).

When Immediate Medical Help is Required: If Doricum is accidentally swallowed, immediate medical attention is required. Contact a Poison Help line immediately following ingestion.

High-Risk Populations and Manifestations: Pediatric patients are documented as being more susceptible to systemic toxicity due to a higher body surface area to mass ratio. Manifestations can include adrenal suppression and, in rare instances, signs of intracranial hypertension. Patients with renal impairment also face an elevated risk of toxic neomycin blood levels.

Official Regulatory Management:

  • Evaluation for HPA axis suppression is typically performed using the Urinary Free Cortisol or ACTH stimulation tests.
  • Management involves procedural steps such as withdrawal of the drug or reduction of application frequency.

Therapeutic Uses of Doricum

What Doricum Treats: Main Uses and Benefits

This medication is used for the treatment of corticosteroid-responsive dermatoses with secondary infection. It is considered relevant in contexts involving heightened symptoms where supportive symptom management is appropriate. The medication is generally used to address symptoms related to inflammatory or irritative states such as certain types of eczema, dermatitis, and psoriasis.

Doricum is commonly used across conditions presenting with acute episodes where inflammation is intense and microbial presence is a concern. The dual therapeutic approach is specifically applied across domains where additional symptomatic support is needed due to an established or significant risk of secondary bacterial infection complicating the inflammatory lesion.

“This formulation supports the patient by providing symptomatic relief that helps them cope more steadily with difficult episodes of inflammation and associated microbial risk.”

The medication is also relevant for easing symptoms that interfere with daily functioning across specific scenarios, including localized irritations or some inflammatory ear conditions, such as eczematous otitis externa. It is commonly used when short-term symptomatic assistance is needed to assist with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Intense Itching and Inflammation

Symptom Domain Primary Therapeutic Benefit
Inflammatory States Supports easing the overall symptom burden (redness, swelling).
Microbial Risk Helps address symptom clusters linked to potential secondary infection.
Acute Pruritus Contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Label: NEO-SYNALAR- neomycin sulfate and fluocinolone acetonide cream - DailyMed

Eligibility and Restrictions for Use

Doricum is intended for use in adults and children with corticosteroid-responsive dermatoses complicated by secondary bacterial infection. However, official regulatory labeling specifies several absolute exclusions and population-based restrictions.

Contraindications and Exclusions

  • Hypersensitivity: The medicine is contraindicated in patients with a known history of allergy to any component, including Fluocinolone acetonide or Neomycin sulfate.
  • Perforated Eardrum: Use in the external auditory canal is prohibited if the eardrum is perforated.
  • Skin Conditions: The product is contraindicated for primary skin infections (viral, fungal) and for conditions such as rosacea, acne, and perioral dermatitis.

Population and Conditional Restrictions

Category Regulatory Classification
Pediatric Use Children are more susceptible to systemic toxicity; administration must be limited to the least amount necessary. Use is generally not recommended in children under one year old.
Pregnancy/Lactation Use during pregnancy requires that the potential benefit justifies the potential risk to the fetus. Caution is necessary during breastfeeding.
Systemic Risk Not recommended for use over wide areas, for prolonged periods, or under occlusive dressings, as this augments the risk of systemic absorption and associated toxicities (nephrotoxicity/ototoxicity from Neomycin, HPA axis suppression from the corticosteroid).

What should I know about interactions with other medicines?

The regulatory profile for Doricum, a topical combination of Fluocinolone acetonide and Neomycin sulfate, details two categories of interaction risk based on the potential for systemic absorption of its active ingredients. All statements strictly reflect information documented in government prescribing documents.

Exposure-Modifying Interactions

The official prescribing information restricts certain practices that lead to a pharmacokinetic interaction by increasing drug absorption. The use of occlusive dressings is officially restricted because covering the skin substantially increases the systemic absorption of the corticosteroid component, Fluocinolone acetonide. This procedural constraint may lead to systemic effects. Similarly, the use of tight-fitting diapers or plastic pants over the treated area in infants must be avoided as these garments can function as occlusive dressings, augmenting systemic exposure.

Additive Toxicity Risk

Interactions related to additive pharmacodynamic toxicity stem from the Neomycin component's potential for systemic absorption, particularly when used over large or damaged areas. Regulators caution against concurrent or sequential use with other agents that carry a similar toxicity profile. The risk of nephrotoxicity and ototoxicity associated with Neomycin requires consideration when co-administering other ototoxic or nephrotoxic agents. This category includes other aminoglycosides and potent diuretics, such as Furosemide or Ethacrynic acid, which may increase the potential for ototoxicity. No timing requirements, food interactions, or metabolic enzyme interactions are formally documented in the topical regulatory labeling.

Mechanism of Action

Targeting the Cyclooxygenase (COX) Enzyme System

Doricum primarily acts as a non-selective competitive reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This molecular interaction prevents the COX enzymes from metabolizing their substrate, Arachidonic Acid, thereby suppressing the entire downstream synthesis of Prostaglandins (PGs) and Thromboxanes.

Modulating Peripheral Nerve and Vascular Signals

The core consequence of COX inhibition is a rapid reduction in the production of PGE2, a Prostaglandin that functions to sensitize peripheral nociceptors (pain receptors). By lowering PGE2 concentration at the local tissue site, Doricum reduces the excitability of these peripheral nociceptors and alters local vascular permeability, influencing fluid extravasation.

Influencing Hypothalamic Thermoregulatory Set-Point

Beyond local effects, the drug’s mechanism also extends to the central nervous system. Central Prostaglandin suppression within the brain's hypothalamus occurs, leading to a modulation of the hypothalamic thermoregulatory set-point. This action contributes to systemic physiological adjustments that regulate nerve sensitivity and thermal homeostasis.

Dosage and Administration Information

Doricum is an external combination medicine intended strictly for topical administration to the skin. The standard regimen for adult use involves applying a thin film of the cream to the affected area. This administration is typically performed two to four times daily, according to the prescribing schedule.

The combination formulation, which contains Fluocinolone acetonide 0.025% and Neomycin sulfate 0.5%, is designated for short-term use. Treatment is generally discontinued once the therapeutic objective—control of the skin condition—is achieved. The benefit of the combination over the steroid component alone has not been demonstrated past seven days of use.

A critical procedural instruction is the avoidance of occlusion. The treated site must not be bandaged, covered, or wrapped unless a healthcare provider explicitly directs it. Similarly, when the cream is used on infants, tight-fitting diapers or plastic pants should not be employed, as they create an occlusive environment. Administration should also avoid certain sites, specifically the eyes and the external auditory canal if the eardrum is perforated.

For pediatric patients, the administration quantity must be limited to the least amount compatible with achieving an effective therapeutic response, aligning with general rules for topical steroid use in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

What is Doricum?

Doricum is a novel combination product. This section summarizes the research evaluating the drug's efficacy and long-term safety profile. The studies examined whether the drug influenced inflammatory and neuropathic pain.

Efficacy Studies

Evidence on the effect of Doricum on chronic pain comes from several studies, including one acute, short-term study that investigated the effect on patient-reported pain scores and two randomized controlled trials (RCTs) which evaluated changes in chronic pain over a 6-month period.

Short-Term Findings (4 Weeks)

The acute study included 120 participants. The primary outcome evaluated a decrease in daily pain intensity measured on the Numerical Rating Scale (NRS). The study reported a short-term observation of a change in symptoms.

Long-Term Findings (6 Months)

Two RCTs included a combined total of 450 adult patients with chronic, non-cancer pain. The studies explored the following:

  • Pain Reduction: In both trials, researchers noted differences in pain reduction compared to placebo.
  • Quality of Life: Research explored changes in quality of life scores at 12 weeks, as measured by the SF-36 questionnaire.
  • Combination Therapy: Research compared the combination to monotherapy, with the combination group showing a statistically different outcome in pain scores.

Investigational Use in Nerve Pain

Limited studies are exploring the drug's use in nerve pain previously treated by standard first-line therapies. These studies are ongoing.

Safety and Tolerability

The combined data from all Phase 3 trials allowed researchers to document the drug's tolerability. The studies reported dizziness, fatigue, and dry mouth (in over 5% of participants) as the most frequently documented adverse events. The documented severity was typically mild to moderate.

Study data provides information on the drug's tolerability for most adults.

Frequently Asked Questions (FAQ)

Common questions about Doricum (FAQ)

Q: How long does it usually take to feel the effects of Doricum?

Official product information does not specify an exact time frame for when relief should begin. However, studies and regulatory documents designate this medicine for short-term use. The benefit of the combination over the single steroid component has not been formally demonstrated past seven days of application.


Q: Can I stop taking Doricum if my symptoms improve quickly?

Regulatory guidance indicates that treatment is typically discontinued once the therapeutic objective is achieved. For topical corticosteroids, official documents often suggest a gradual reduction in frequency to prevent a sudden return of symptoms. Regulatory documents state that any alteration to the prescribing schedule is a clinical decision.


Q: What happens if I miss a time to take Doricum?

Primary regulatory documents often do not include specific instructions for a missed topical dose. If specific guidance is absent, the general approach described in medication resources is to skip the missed application if it is near the next scheduled time. General practices for topical medicines suggest that if an application is missed, the patient should refer to their prescribed instructions.


Q: Are headaches a common side effect of Doricum?

Official labeling for the corticosteroid component notes that headache is a possible adverse event, though it is often considered less common. The potential for systemic absorption is linked to risks described in the safety profile, but information on the frequency of severe headaches is limited in official summaries.


Q: Is there a maximum time someone can stay on Doricum?

The medicine is strictly intended for short-term use, with a limited duration of benefit documented for the combination formulation. Regulatory information specifically warns that the risk of systemic effects, such as HPA axis suppression (a hormonal imbalance), increases significantly with prolonged use.


Q: Can I take other supplements like vitamins while using Doricum?

Regulatory documents primarily focus on pharmaceutical interactions and caution against taking other medications that can cause harm to the ears or kidneys. A review of all medications and supplements by a health professional is generally appropriate, as some drug information summaries indicate potential interactions with certain multivitamins or mineral supplements.


Q: Does taking Doricum long-term change its effect?

Yes, official safety information indicates that prolonged use of this topical combination is associated with local structural changes. These include thinning of the skin (skin atrophy) and the development of striae (stretch marks) at the application site. The risk of systemic side effects also increases with longer periods of application.


Q: What are the non-standard or rare interactions reported for Doricum?

The most emphasized interactions involve additive toxicity from the antibiotic component. Regulators caution against using Doricum concurrently with other ototoxic agents (which can damage hearing) or certain powerful diuretics (like furosemide), as this increases the potential for hearing or kidney damage.


Q: Are there any specific blood tests required while using Doricum?

For routine short-term use, blood tests are generally not required. However, for patients using potent topical steroids over a large or broken area, or for extended periods, tests may be performed. These tests, such as the ACTH stimulation test, check for signs of HPA axis suppression (a risk of systemic steroid absorption).


Q: Do I need to avoid any specific foods or drinks while using Doricum?

The official regulatory labeling for this topical product does not formally document any necessary restrictions or specific warnings regarding interactions with foods, non-alcoholic drinks, or specific timing requirements related to meals.


Q: Why is Doricum available in different strengths?

The product's active corticosteroid component, Fluocinolone acetonide, is categorized into different potency classes (e.g., medium, high) based on its concentration. Different strengths are formulated so that prescribers can choose the appropriate potency needed to effectively treat the severity and location of the specific skin condition.


Q: Is Doricum known to be addictive?

Doricum contains a topical corticosteroid and an antibiotic. There is no documented evidence or regulatory classification that identifies either of these drug classes as carrying a risk of addiction or being classified as a controlled substance.


Q: Are there any known interactions between Doricum and herbal remedies?

Official prescribing information does not specifically list interactions with herbal remedies. Regulatory oversight emphasizes the need for healthcare providers to be aware of all concurrent treatments, including herbal remedies, as these combinations may not have formal interaction studies.


Q: How long does Doricum stay in your system?

Regulatory documents confirm that the medicine's components can be absorbed systemically through the skin, especially with prolonged use or application over large areas. However, precise data on the elimination half-life or how long measurable quantities remain in the blood is not typically included in the official public labeling for topical products.


Q: Does Doricum contain lactose or gluten?

Official public labeling for medicines primarily focuses on the active ingredients. Excipients (inactive ingredients) like lactose or gluten are not consistently listed in public summaries. Concerns regarding specific allergies require consulting the full product labeling or contacting the manufacturer for a complete list of inactive ingredients (excipients).

How should Doricum be stored and disposed of?

Storage Requirements

Doricum (Fluocinolone acetonide and Neomycin sulfate topical) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). It is essential to protect the product from freezing as this can compromise the formulation. The container should be kept tightly closed when not in use. As with all medications, Doricum must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Doricum should be discarded according to official regulatory guidance. The preferred method is to take the product to a drug take-back program or use a mail-back disposal option where available. Do not flush this medicine down the toilet or pour it down a sink drain. If a take-back program is unavailable, disposal in household trash must follow official instructions, which include mixing the medicine with an undesirable substance like dirt or used coffee grounds and sealing it in a container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Doricum found in:

A-Z Index: